×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Bladder

Gina Columbus
To take the next step in this research, investigators are now combining immunotherapies together, or with chemotherapy, to create added benefits and more durable, long-lasting responses.
Angelica Welch
There were monumental advances in the treatment of bladder cancer during the year 2017, with five approvals for checkpoint inhibitors in both the first and second line setting
Ariela Katz
When given neoadjuvant chemotherapy before getting a radical cystectomy, patients with the basal subtype of muscle-invasive bladder cancer (MIBC) saw significantly improved overall survival (OS) compared to those who had a cystectomy alone, according to a recent study.
Andy Seibert
In the midst of all of the things that tie us together, it’s been what many would consider the most challenging shared experience a mother and son can have – facing and surviving cancer – that has been a defining feature of our relationship and ultimately one of the most overwhelming blessings of life.
Danielle Bucco
Quality of care for patients being treated for urothelial carcinoma could be improved by having a multidisciplinary team treat the patient, says Robert Jones, M.D.
Angelica Welch
“It is not so much that the biology is changing; it’s that our knowledge of the biology is improving,” said Brant Inman, M.D.
Gina Columbus
After years with few advancements, five new agents were approved to treat bladder cancer within the last year. CURE spoke with Terence Friedlander, M.D. about the shifting treatment paradigm for patients with the disease.
Gina Columbus

Sumanta Kumar Pal, M.D., associate professor, Department of Medical Oncology, City of Hope, covered the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.
Arlene Weintraub
Immunotherapies known as checkpoint inhibitors are so promising in bladder cancer that many patients want them as first treatments — before they’ve been proven in that setting.
Virginia Powers, Ph.D.
Keytruda (pembrolizumab) produced better overall survival (OS) rates than chemotherapy for patients with recurrent, advanced urothelial carcinoma.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable